PubRank

T L Wright

Author PubWeight™ 113.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999 5.32
2 Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000 3.74
3 "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994 3.33
4 Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A 1999 3.30
5 Molecular virology and pathogenesis of hepatitis B. Lancet 1993 3.27
6 HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000 2.60
7 Gastrointestinal Kaposi's sarcoma in patients with acquired immunodeficiency syndrome. Endoscopic and autopsy findings. Gastroenterology 1985 1.90
8 Acute hepatitis C. Hepatology 2001 1.82
9 The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997 1.68
10 The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995 1.67
11 Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med 2001 1.55
12 A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995 1.54
13 Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut 2003 1.51
14 Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001 1.49
15 Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999 1.48
16 Are HCV-infected individuals candidates for hepatitis A vaccine? Lancet 1998 1.46
17 Nitric oxide-induced mutations in the HPRT gene of human lymphoblastoid TK6 cells and in Salmonella typhimurium. Environ Mol Mutagen 2000 1.46
18 Characterization of non-transferrin-bound iron clearance by rat liver. J Biol Chem 1986 1.46
19 Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology 1992 1.41
20 Hepatitis C and liver transplantation. J Hepatol 2001 1.40
21 Pruritus as a symptom of hepatitis C. J Am Acad Dermatol 1994 1.39
22 Recombinational repair is critical for survival of Escherichia coli exposed to nitric oxide. J Bacteriol 2001 1.33
23 Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem 2000 1.32
24 Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 1985 1.32
25 The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001 1.30
26 Mutation of human keratin 18 in association with cryptogenic cirrhosis. J Clin Invest 1997 1.24
27 Liver transplantation for patients with hepatitis B: what have we learned from our results? Hepatology 1991 1.21
28 A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000 1.21
29 Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996 1.19
30 Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996 1.17
31 Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000 1.17
32 Failure to detect hepatitis C virus genome in human secretions with the polymerase chain reaction. Hepatology 1991 1.15
33 Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology 1998 1.11
34 Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998 1.05
35 Hepatitis C viral infection in liver transplant recipients. Hepatology 1992 1.04
36 Hepatitis C virus: quantitation and distribution in liver. J Med Virol 1997 1.03
37 Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology 2001 1.03
38 Hepatitis C and liver transplantation. Gut 1999 1.03
39 Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002 1.03
40 Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia 1999 1.01
41 Cholestatic hepatitis C in liver allografts. Liver Transpl Surg 1998 0.97
42 Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation. Gastroenterology 1996 0.96
43 Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet 1993 0.96
44 Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*. J Viral Hepat 2006 0.95
45 Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes. Hepatology 1993 0.93
46 Splenic injury following colonoscopy. Gastrointest Endosc 1990 0.92
47 Hepatitis C in patients undergoing liver transplantation. Ann Intern Med 1991 0.92
48 Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg 1996 0.91
49 Hepatitis C virus in the setting of transplantation. Semin Liver Dis 1995 0.90
50 Inhibition of erythroid colony formation by autologous bone marrow adherent cells from patients with the anemia of chronic disease. Blood 1983 0.88
51 Hepatitis B and C coinfections and persistent hepatitis B infections: clinical outcome and liver pathology after transplantation. Hepatology 1996 0.88
52 Pargyline-induced myopathy with histochemical characteristics of Duchenne muscular dystrophy. Neurology 1974 0.86
53 Etiology of fulminant hepatic failure: is another virus involved? Gastroenterology 1993 0.85
54 Lack of evidence for hepatitis C virus in corneas of seropositive cadavers. Am J Ophthalmol 1994 0.84
55 Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa. J Rheumatol 1993 0.84
56 Update on clinical trials in the treatment of hepatitis B. J Gastroenterol Hepatol 1999 0.83
57 Direct functional analysis of epitope-specific CD8+ T cells in peripheral blood. Viral Immunol 2001 0.83
58 Self-efficacy expectancies, outcome expectancies, and the persistence of pain control in childbirth. J Pers Soc Psychol 1983 0.82
59 New developments in the treatment of hepatitis C. Gut 2003 0.82
60 Persistent hepatitis B virus following interferon alfa therapy and liver transplantation. Gastroenterology 1991 0.81
61 Hepatitis C infection in transplantation. Clin Liver Dis 1997 0.81
62 Interferon therapy for hepatitis C. Lancet 1996 0.81
63 Antienvelope antibodies are protective against GBV-C reinfection: evidence from the liver transplant model. J Med Virol 1998 0.81
64 Cryoglobulinemia presenting after liver transplantation. Gastroenterology 1996 0.80
65 Interaction of natural and synthetic albumin polymers with hepatocytes. Hepatology 1987 0.80
66 Age differences in coping: does less mean worse. Int J Aging Hum Dev 1989 0.79
67 Detection of hepatitis C after liver transplantation. Four serologic tests compared. Am J Clin Pathol 1995 0.79
68 Hepatitis C and liver transplantation. J Gastroenterol Hepatol 1996 0.79
69 Evolution of viral quasispecies in interferon-treated patients with chronic hepatitis C virus infection. J Hepatol 1999 0.79
70 Abnormal intrafibrillar monoamines in sex-linked muscular dystrophy. Neurology 1973 0.78
71 Lithium teratogenicity. Lancet 1970 0.78
72 Hepatitis C virus detection by single-round PCR specific for the terminal 3' noncoding region. J Clin Microbiol 1996 0.78
73 GB virus C (GBV-C/HGV) and E2 antibodies in children preliver and postliver transplant. Pediatr Res 1999 0.78
74 Oxygen fugacities directly measured in magmatic gases. Science 1966 0.78
75 Hepatitis C: an overview. Annu Rev Med 1995 0.78
76 Thalamic hemorrhage with speech disorder. Trans Am Neurol Assoc 1976 0.78
77 Cytomegalovirus infection and vanishing bile duct syndrome: culprit or innocent bystander? Hepatology 1992 0.78
78 "Silent killer" or benign disease? The dilemma of hepatitis C virus outcomes. Hepatology 2000 0.78
79 Serum ALT: tarnished gold standard for interferon response in hepatitis C virus infection. Hepatology 1994 0.78
80 Therapeutic advances in the management of hepatitis B and hepatitis C. Curr Opin Infect Dis 2001 0.78
81 Viral evolution of hepatitis C in injection drug users. J Viral Hepat 2005 0.77
82 Hepatitis after liver transplantation: the role of the known and unknown viruses. Liver Transpl Surg 1998 0.77
83 Interpersonal trust, trustworthiness and shoplifting in high school. Psychol Rep 1977 0.77
84 Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study. Kidney Int 1994 0.77
85 Hepatitis G virus: what is the next step? Liver Transpl Surg 1997 0.77
86 Hepatitis G virus in patients with cryptogenic liver disease undergoing liver transplantation. Hepatology 1997 0.77
87 Radiation-induced cerebrovascular disease in children. Neurology 1976 0.76
88 Hepatitis B virus infection and liver transplantation. Gut 1997 0.76
89 Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. Clin Transplant 1995 0.76
90 A social relations model test of Sullivan's anxiety hypothesis. J Pers Soc Psychol 1987 0.76
91 Listeners' identification of human-imitated animal sounds. Percept Mot Skills 1983 0.76
92 Antibody response to hepatitis C virus infection after liver transplantation. Am J Gastroenterol 1994 0.76
93 Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantation. Am J Transplant 2006 0.76
94 Hepatitis C in liver transplant recipients. Transplant Proc 1991 0.76
95 Hepatitis C virus--a pathogen for all people. West J Med 1996 0.75
96 The dilemma of disease progression in hepatitis C patients with normal serum aminotransferase levels. Am J Med 2000 0.75
97 Is the hepatocyte a Trojan horse for hepatitis C virus? Gut 1998 0.75
98 Antibody to GBV-C second envelope glycoprotein (anti-GBV-C E2): is it a marker for immunity? J Med Virol 1997 0.75
99 Summary of the first international symposium on viral hepatitis. Antiviral Res 1999 0.75
100 Hepatitis C virus and the host: An imbalance induced by immunosuppression? Hepatology 2000 0.75
101 Hepatitis C infection in the transplant recipient. Infect Dis Clin North Am 1995 0.75
102 Treatment of hepatitis C: a decision that needs careful consideration. Am J Med 1999 0.75
103 Overview of HBV therapy. Adv Exp Med Biol 1999 0.75
104 Treatment strategies for recurrent hepatitis C after liver transplantation. Clin Liver Dis 1999 0.75
105 Igneous petrology. Science 1981 0.75
106 Maintaining competency in long-term care. Perspectives 1999 0.75
107 Hepatitis C virus in the transplant setting. Antivir Ther 1998 0.75
108 An extension of Jessor and Jessor's problem behavior theory from marijuana to cigarette use. Int J Addict 1982 0.75
109 Hepatitis C virus infection in the immunocompromised patient. Semin Gastrointest Dis 1995 0.75
110 The polyalbumin hypothesis: where is it in 1989? Gastroenterology 1989 0.75
111 Scholarly productivity of geriatrics senior faculty members and faculty trainees compared with that of other health professions educators. Acad Med 1992 0.75
112 Listeners' discrimination of real and human-imitated animal sounds. Percept Mot Skills 1984 0.75
113 Treatment for recurrent viral hepatitis after liver transplantation. J Hepatol 1997 0.75
114 Hepatitis G: a virus in search of a disease. Hepatology 1996 0.75
115 Kilauea volcano: the 1967-68 summit eruption. Science 1969 0.75
116 New approaches to treatment of chronic viral hepatitis. Pathology (Phila) 1994 0.75
117 Therapy for chronic hepatitis B infection. Adv Exp Med Biol 1996 0.75
118 Elderfield pyrimidine mustard in chronic lymphocytic leukemia. Clin Pharmacol Ther 1970 0.75
119 Liver transplantation as a model to study hepatitis C virus infection. Methods Mol Med 1999 0.75
120 Antibody to the host cellular gene-derived epitope GOR-1 in liver transplant recipients with hepatitis C virus infection. Transplantation 1997 0.75
121 Prophylaxis and treatment strategies for chronic viral hepatitis in liver transplant patients. Clin Liver Dis 1997 0.75
122 Low incidence of intraspousal transmission of hepatitis C virus after liver transplantation. Liver Transpl Surg 1995 0.75
123 Education in geriatric medicine: the TCGEC faculty development model. Gerontol Geriatr Educ 1988 0.75
124 Clinicopathological conference: hepatitis C in a patient with human immunodeficiency virus infection. Hepatology 2000 0.75
125 Viral hepatitis and liver transplantation. J Gastroenterol Hepatol 1999 0.75
126 An active volcano: mount etna. Science 1986 0.75
127 Hepatitis B and C viruses: molecular identification and targeted antiviral therapies. Proc Assoc Am Physicians 1998 0.75
128 Hepatitis. Advances in antiviral therapy for hepatitis. Lancet 1999 0.75